Compare · MRK vs UPC
MRK vs UPC
Side-by-side comparison of Merck & Company Inc. (MRK) and Universe Pharmaceuticals Inc. (UPC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and UPC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $204.35B, about 6857.9x UPC ($29.8M).
- MRK has been more active in the news (9 items in the past 4 weeks vs 1 for UPC).
- MRK has more recent analyst coverage (25 ratings vs 0 for UPC).
- Company
- Merck & Company Inc.
- Universe Pharmaceuticals Inc.
- Price
- $111.84-2.43%
- $2.89-0.69%
- Market cap
- $204.35B
- $29.8M
- 1M return
- -6.32%
- -
- 1Y return
- +34.42%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 1
- Recent ratings
- 25
- 0
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Universe Pharmaceuticals Inc.
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief for common chronic health conditions in the elderly for the physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'an, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.
Latest MRK
- Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
- Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
- FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir)
- European Commission Approves Merck's ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
- New Survey Shows HPV Awareness Isn't Keeping Pace with Certain HPV-Related Cancer Trends in Canada
- Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
- SEC Form DEFA14A filed by Merck & Company Inc.
- SEC Form DEF 14A filed by Merck & Company Inc.
- Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
- Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
Latest UPC
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by new insider Yang Lin (Lydia)
- SEC Form 3 filed by new insider Lai Gang
- SEC Form 3 filed by Universe Pharmaceuticals Inc.
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure
- SEC Form 20-F filed by Universe Pharmaceuticals Inc.